Topical CP-690,550 For Chronic Plaque Psoriasis

Back to Search
Print
Bookmark Trial

NCT00678561

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Irvine, California, 92697, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Having chronic plaque psoriasis for at least 6 months

- Able to withdraw all prior psoriasis treatments

- Must agree to avoid prolonged exposure to the sun and avoid use of tanning booths or other ultraviolet light sources during the study

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Evidence of active, latent, or inadequately treated infection with Mycobacterium
tuberculosis


- Pregnant or lactating women


- Unwilling to use appropriate contraceptive methods

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

PsoriasisStudy Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept NCT00992394
  1. Besancon,
  2. Limoges,
  3. Lyon Cedex 03,
  4. Nantes Cedex 01,
  5. Nice Cedex 03,
  6. Paris,
  7. Pierre Benite,
  8. Poitiers,
  9. Reims,
  10. Toulouse Cedex,
  11. Berlin,
  12. Bochum,
  13. Erlangen,
  14. Frankfurt am Main,
  15. Freiburg,
  16. Hamburg,
  17. Osnabrueck,
  18. Athens,
  19. Thessaloniki,
  20. Budapest,
  21. Debrecen,
  22. Miskolc,
  23. Szeged,
  24. Catania,
  25. Chieti,
  26. Parma,
  27. Santander, Cantabria
  28. Alcorcon, Madrid
  29. Getafe, Madrid
  30. Alicante,
  31. Madrid,
  32. Malaga,
  33. Istanbul, Capa
  34. Ankara, Etlik
  35. Ankara, Etlik
  36. Ankara, Etlik
  37. Istanbul, Fatih
  38. Bursa, Gorukle
  39. Pendik, Istanbul
  40. Ankara, Sihhiye
  41. Ankara, Sihhiye
  42. Ankara,
  43. Bornova / Izmir,
  44. Abu Dhabi, UAE
  45. Harrogate,
  46. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
PsoriasisEffectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis NCT00678210
  1. Tucson, Arizona
  2. Little Rock, Arkansas
  3. Oceanside, California
  4. Jacksonville, Florida
  5. Miami, Florida
  6. West Dundee, Illinois
  7. Boston, Massachusetts
  8. Boston, Massachusetts
  9. Worcester, Massachusetts
  10. Saint Louis, Missouri
  11. East Windsor, New Jersey
  12. Paramus, New Jersey
  13. New York, New York
  14. Rochester, New York
  15. Winston Salem, North Carolina
  16. Cleveland, Ohio
  17. Norman, Oklahoma
  18. Lake Oswego, Oregon
  19. Portland, Oregon
  20. Portland, Oregon
  21. Philadelphia, Pennsylvania
  22. Greer, South Carolina
  23. Greer, South Carolina
  24. Mt. Pleasant, South Carolina
  25. Dallas, Texas
  26. Houston, Texas
  27. Webster, Texas
  28. Salt Lake City, Utah
  29. Norfolk, Virginia
  30. Vancouver, British Columbia
  31. Moncton, New Brunswick
  32. St. John's, Newfoundland and Labrador
  33. Halifax, Nova Scotia
  34. Halifax, Nova Scotia
  35. Halifax, Nova Scotia
  36. Barrie, Ontario
  37. London, Ontario
  38. North Bay, Ontario
  39. Waterloo, Ontario
  40. Windsor, Ontario
  41. Laval, Quebec
  42. Montreal, Quebec
  43. Montreal, Quebec
  44. Quebec,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
PsoriasisTopical CP-690,550 For Chronic Plaque Psoriasis NCT00678561
  1. Irvine, California
  2. San Diego, California
  3. Chicago, Illinois
  4. Boston, Massachusetts
  5. Ann Arbor, Michigan
  6. Fridley, Minnesota
  7. Saint Louis, Missouri
  8. High Point, North Carolina
  9. WinstoN Salem, North Carolina
  10. Portland, Oregon
  11. Portland, Oregon
  12. Austin, Texas
  13. Salt Lake City, Utah
  14. Surrey, British Columbia
  15. St. John's, Newfoundland and Labrador
  16. Waterloo, Ontario
  17. Montreal, Quebec
  18. Montreal, Quebec
  19. Quebec,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
PsoriasisA One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis NCT01276639
  1. Birmingham, Alabama
  2. Irvine, California
  3. San Diego, California
  4. Santa Monica, California
  5. Denver, Colorado
  6. New Haven, Connecticut
  7. Ocala, Florida
  8. Tampa, Florida
  9. Alpharetta, Georgia
  10. Atlanta, Georgia
  11. Newnan, Georgia
  12. Springfield, Illinois
  13. Indianapolis, Indiana
  14. Boston, Massachusetts
  15. Boston, Massachusetts
  16. Omaha, Nebraska
  17. New York, New York
  18. Rochester, New York
  19. Raleigh, North Carolina
  20. Raleigh, North Carolina
  21. Norman, Oklahoma
  22. Lake Oswego, Oregon
  23. Pittsburgh, Pennsylvania
  24. Johnston, Rhode Island
  25. Knoxville, Tennessee
  26. Dallas, Texas
  27. Dallas, Texas
  28. Houston, Texas
  29. Spokane, Washington
  30. Spokane, Washington
  31. Wenatchee, Washington
  32. Madison, Wisconsin
  33. Winnipeg, Manitoba
  34. St. John's, Newfoundland and Labrador
  35. Halifax, Nova Scotia
  36. Barrie, Ontario
  37. Markham, Ontario
  38. North Bay, Ontario
  39. Oakville, Ontario
  40. Ottawa, Ontario
  41. Waterloo, Ontario
  42. Quebec,
  43. Barranquilla, Atlantico
  44. Bogot, Cundinamarca
  45. Berlin,
  46. Berlin,
  47. Bonn,
  48. Dresden,
  49. Hamburg,
  50. Kiel,
  51. Muenster,
  52. Schwerin,
  53. Vechta,
  54. Wuppertal,
  55. Kecskemet,
  56. Nyiregyhaza,
  57. Pecs,
  58. Maebashi-shi, Gunma
  59. Sapporo, Hokkaido
  60. Chuo-ku, Kobe
  61. Kumamoto-shi, Kumamoto
  62. Shinjyuku-ku, Tokyo
  63. Monterrey, Nuevo Leon
  64. Poznan,
  65. Szczecin,
  66. Wroclaw,
  67. Wroclaw,
  68. Belgrade,
  69. Tainan,
  70. Taipei,
  71. Simferopol, Crimea
  72. Kharkiv,
  73. Kyiv,
  74. Ternopil,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Topical CP-690,550 For Chronic Plaque Psoriasis
Official Title  ICMJE Phase 2A Randomized, Double-Blind, Vehicle-Controlled, Intra-Individual Comparison Trial Assessing Safety, Toleration, Pharmacokinetics And Pilot Efficacy Of 4 Weeks Treatment With Topical CP-690,550 In Chronic Plaque Psoriasis
Brief Summary Study will test effectiveness of an experimental drug applied once or twice daily to two psoriasis plaques. Requires 1 clinic visit each week for 5 weeks.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Psoriasis
Intervention  ICMJE
  • Drug: CP-690,550
    Topical treatment once daily for 28 days
  • Drug: CP-690,550
    Topical treatment twice daily for 28 days
  • Drug: Placebo Vehicle
    Topical treatment once daily for 28 days
  • Drug: Placebo Vehicle
    Topical treatment twice daily for 28 days
Study Arms  ICMJE
  • Experimental: 2% CP-690,550 QD
    Intervention: Drug: CP-690,550
  • Experimental: 0.2% CP-690,550 QD
    Intervention: Drug: CP-690,550
  • Experimental: 0.02% CP-690,550 QD
    Intervention: Drug: CP-690,550
  • Experimental: 2% CP-690,550 BID
    Intervention: Drug: CP-690,550
  • Experimental: 0.2% CP-690,550 BID
    Intervention: Drug: CP-690,550
  • Experimental: 0.02% CP-690,550 BID
    Intervention: Drug: CP-690,550
  • Placebo Comparator: Placebo Vehicle QD
    Intervention: Drug: Placebo Vehicle
  • Placebo Comparator: Placebo Vehicle BID
    Intervention: Drug: Placebo Vehicle
Publications * Ports WC, Feldman SR, Gupta P, Tan H, Johnson TR, Bissonnette R. Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design. J Drugs Dermatol. 2015 Aug;14(8):777-84.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 14, 2009)		81
Original Estimated Enrollment  ICMJE
 (submitted: May 13, 2008)		98
Actual Study Completion Date  ICMJE July 2009
Actual Primary Completion Date July 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Having chronic plaque psoriasis for at least 6 months
  • Able to withdraw all prior psoriasis treatments
  • Must agree to avoid prolonged exposure to the sun and avoid use of tanning booths or other ultraviolet light sources during the study

Exclusion Criteria:

  • Evidence of active, latent, or inadequately treated infection with Mycobacterium tuberculosis
  • Pregnant or lactating women
  • Unwilling to use appropriate contraceptive methods
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00678561
Other Study ID Numbers  ICMJE A3921038
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP